Shares of Abivax fell sharply in morning trading, declining roughly 9.8% to $88.77 as investor anxiety about safety signals linked to its lead oral therapy obefazimod resurfaced ahead of a key safety data readout. The session opened near the prior close of $98.43 before sellers took control and pushed the price down to an intraday low of $74.79.
The immediate pressure on the stock traces back to an early June development in Abivax's Phase 3 ABTECT maintenance trial. While the study posted strong efficacy figures - approximately 50% to 51% clinical remission versus 10.4% for placebo - reports of non-melanoma skin cancers and other malignancies emerged, concentrated mainly among patients older than 60 who were assigned the higher 50 mg dose arm. That disclosure precipitated a dramatic market move earlier in June, with the company suffering a single-day decline in excess of 40%.
Following the June disclosures, Jefferies downgraded the shares to Hold and reduced its price target. The safety concerns also triggered multiple securities fraud investigations led by law firms including Schall, Gross, and Levi & Korsinsky. Analysts had flagged the upcoming safety readout as a material, binary near-term risk - as reflected by at least one analyst maintaining a $170 price target as recently as June 16 explicitly "ahead of a key ulcerative colitis safety readout."
Today’s renewed selloff unfolded against a constructive broader market environment, with both the S&P 500 and the Nasdaq trading higher. That indicates macroeconomic forces were not the proximate cause of the move; rather, company-specific safety and legal overhangs drove the decline. Analysts covering the company - among them Barclays, Piper Sandler, Guggenheim, and BTIG - largely retain Buy ratings on the shares, although many have trimmed price targets since the early June selloff.
Technically, the stock had already shown signs of fragility, slipping roughly 5% over the prior week as it attempted to recover from the June collapse. That partial rebound left underlying regulatory uncertainty unresolved, creating a scenario in which fresh safety data or commentary could trigger another selloff. The combination of the lingering safety catalyst, active litigation, and a stock that had recovered without clear resolution of those issues set the stage for today's pronounced move.
Despite the present market turbulence, Abivax continues to project that its New Drug Application filing with the U.S. Food and Drug Administration remains on track for late 2026. The path to regulatory clarity, however, appears to be complicated by the safety signals and the attendant legal inquiries that followed the Phase 3 disclosures.
Market context and investor takeaway
Investors reacted to a concentrated set of company-specific risks rather than to broad market weakness. The stock's intraday swing - opening near $98.43 and reaching $74.79 at its low - highlights how acute safety developments can rapidly override constructive sector or market conditions. The presence of ongoing securities investigations and analyst downgrades add extra layers of uncertainty for holders and potential buyers.